Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Ralph Lauren Corp (RL) Price & Performance

Cassava Sciences IncTrade
Ralph Lauren CorpTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Ralph Lauren Corp — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Ralph Lauren Corp trades at $398 (market cap $24.24B). The key difference: Ralph Lauren Corp is far larger — about 507.6× Cassava Sciences Inc's market cap, and Ralph Lauren Corp pays a 0.92% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNARL
Market Cap
$47.75M$24.24B
Sector
HealthConsumer Cyclical
52-Week High
$4.64$414.25
52-Week Low
$0.87$285.35
Enterprise Value
-$34.93M$25.31B
Dividend Yield
0.92%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Ralph Lauren Corp

Ralph Lauren (RL) trades at $395.53, down 0.08% on the day, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q1 2027 EPS of $4.59 exceeding expectations of $4.32, driven by robust demand and margin expansion. Revenue growth accelerated to 13% in constant currency, and the company updated its fiscal 2027 outlook upward. Key support lies at $388, with resistance at $402.

The investment outlook is positive, supported by earnings momentum, brand strength, and a 66% analyst buy rating. Risks include high valuation multiples, such as a P/E of 24.92, and sensitivity to consumer spending trends. The consensus price target of $456.50 implies 15% upside potential from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Ralph Lauren Corp

Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.

Read more on RL